CYP3A4 and liver disorder: In patients without a clinically significant liver disease, investigation into the effect of chronic hepatitis C on pharmacokinetics of a probe of CYP3A enzymes called midazolam has uncovered weaker CYP3A4 activity in patients with chronic hepatitis C than in healthy volunteers [398,399].